


What is claimed is:

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof,



wherein


R_1 is selected from C_{1-6} alkylthio, 5-6 membered heteroaryl, C_{2-6} alkynyl and C_{3-6} cycloalkyl each of which is optionally substituted with 1, 2 or 3 R or R';


T_1 is selected from N or CH;

T_2 is selected from N or $C(R_2)$;

R_2 is selected from H, F, Cl, Br, I;

R_3 is selected from H, halogen, CN, NH_2 , OH, or from C_{1-6} alkyl which is optionally substituted with 1, 2 or 3 R or R';


R is selected from halogen, OH, NH_2 , CN, COOH, , or from C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{3-6} cycloalkyl, 3-6 membered heterocycloalkyl, 3-6 membered heterocycloalkyl- $C(=O)-$, 3-6 membered heterocycloalkyl- $(CH_2)_{1-3}-$ each of which is optionally substituted with 1, 2 or 3 R';

R' is selected from F, Cl, Br, I, CN, OH, NH_2 , COOH, Me, $NHCH_3$, $N(CH_3)_2$, , ;


"hetero-" in the 5-6 membered heteroaryl, C_{1-6} heteroalkyl, C_{3-6} cycloalkyl, 3-6 membered heterocycloalkyl is selected from N, -S-, -O-, -NH-;

in any one of the aforesaid cases, the number of heteroatom(s) or heteroatomic group(s) is each independently selected from 1, 2 or 3.







2. The compound or the pharmaceutically acceptable salt thereof according to claim 1,

wherein, R is selected from F, Cl, Br, I, OH, NH₂, CN, COOH, , or from C₁₋₃ alkyl, C₁₋₃ heteroalkyl, C₃₋₆ cycloalkyl, 3-6 membered heterocycloalkyl, 3-6 membered heterocycloalkyl-C(=O)-, 3-6 membered heterocycloalkyl-CH₂- each of which is optionally substituted with 1, 2 or 3 R'.







3. The compound or the pharmaceutically acceptable salt thereof according to claim 2,


wherein, R is selected from F, Cl, Br, I, OH, NH₂, CN, COOH, , or from Me, Et, C₁₋₃ alkylthio, C₃₋₆ cycloalkyl, azetidiny, pyrrolidinyl, piperazinyl, morpholinyl, piperazinyl-C(=O)-, morpholinyl-C(=O)-, pyrrolidinyl-C(=O)-, piperazinyl-CH₂-, morpholinyl-CH₂-, pyrrolidinyl-CH₂- each of which is optionally substituted with 1, 2 or 3 R'.

4. The compound or the pharmaceutically acceptable salt thereof according to claim 3,

wherein, R is selected from F, Cl, Br, I, OH, NH₂, CN, COOH, , or from Me, Et, , , , , , , , , each of which is optionally substituted with 1, 2 or 3 R'.

5. The compound or the pharmaceutically acceptable salt thereof according to claim 4,

wherein, R is selected from F, Cl, Br, I, OH, NH₂, Me, Et, CN, COOH, , , , , , , , , , ,








6. The compound or the pharmaceutically acceptable salt thereof according to any one of claims 1-5, wherein, R_1 is selected from C_{1-3} alkylthio, C_{2-4} alkynyl, C_{3-5} cycloalkyl each of which is optionally substituted with 1, 2 or 3 R or R'.

7. The compound or the pharmaceutically acceptable salt thereof according to claim 6,










wherein, R_1 is selected from , , , ,  each of which is optionally substituted with 1, 2 or 3 R or R'.

8. The compound or the pharmaceutically acceptable salt thereof according to claim 7,


wherein, R_1 is selected from , , , , , , , , , , , , , , .


9. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1-5, wherein, R_1 is selected from pyridyl, pyrazolyl, imidazolyl, thienyl, oxazolyl, isoxazolyl each of which is optionally substituted with 1, 2 or 3 R or R'.

10. The compound or the pharmaceutically acceptable salt thereof according to claim

9, wherein, R_1 is selected from , , , , , , , ,  each of which is optionally substituted with 1, 2 or 3 R or R'.

[illegible]

8 or 11, wherein, R₁ is selected from 



13. The compound or the pharmaceutically acceptable salt thereof according to any one of claims 1-5, wherein, T₂ is selected from N, CH or C(F).


14. The compound or the pharmaceutically acceptable salt thereof according to any one of claims 1-5, wherein, R₃ is selected from H, halogen, CN, NH₂, OH, or from C₁₋₃ alkyl which is optionally substituted with 1, 2 or 3 R or R'.

15. The compound or the pharmaceutically acceptable salt thereof according to claim 14, wherein, R₃ is selected from H, F, Cl, Br, I, CN, NH₂, OH, or from Me and Et each of which is optionally substituted with 1, 2 or 3 R or R'.


16. The compound or the pharmaceutically acceptable salt thereof according to claim 15, wherein, R₃ is selected from H, F, Cl, Br, I, CN, NH₂, OH, Me, Et, CF₃.

17. The compound or the pharmaceutically acceptable salt thereof according to any


one of claims 1-5, wherein, the structural unit



is selected from





18. The compound or the pharmaceutically acceptable salt thereof according to any one of claim 1-17, which is selected from




wherein, R_1 and R_3 are as defined in claims 1-17.


19. A compound represented by a formula selected from












20. The compound or the pharmaceutically acceptable salt thereof according to claim 19, which is selected from







21. Use of the compound or the pharmaceutically acceptable salt thereof according to any one of claims 1-20 in the preparation of a medicament for treating diseases associated with influenza viruses.